| 摘要 |
Compositions for preventing or treating inflammatory diseases such as inflammatory diseases of the joint, multiple sclerosis, leukemia, ischemic injury or reperfusion injury, are described. A fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) with all or part of a constant domain of a heavy or light chain of human immunoglobulin at the carboxy terminus is also described. Three useful forms of IL-1ra (IL-1raa, IL-1raß and IL-1rax) and variants thereof are disclosed and described in US Patent No. 5,075,222. Described herein are modified forms of IL-1ra. The modified forms of IL-1ra include polypeptides in which amino acids have been deleted from, inserted into and substituted for residues within the amino acid sequence of IL-1ra. For IL-1ra addition variants, each polypeptide may include an amino- and/or carboxyl-terminus fusion ranging in length from 1>100 residues.
|
